» Journals » Technol Cancer Res Treat

Technology in Cancer Research & Treatment

Technology in Cancer Research & Treatment is a peer-reviewed journal that focuses on the latest advancements in technology and its applications in cancer research and treatment. It covers a wide range of topics including imaging techniques, molecular diagnostics, targeted therapies, bioinformatics, and nanotechnology. The journal provides a platform for researchers, clinicians, and engineers to share their innovative approaches and discoveries, ultimately contributing to the improvement of cancer diagnosis, prognosis, and therapy.

Details
Abbr. Technol Cancer Res Treat
Start 2002
End Continuing
Frequency Bimonthly
p-ISSN 1533-0346
e-ISSN 1533-0338
Country United States
Language English
Metrics
h-index / Ranks: 4950 72
SJR / Ranks: 7389 609
CiteScore / Ranks: 6169 4.30
JIF / Ranks: 3791 2.8
Recent Articles
1.
Li L, Hao Y, Dong L, Qiao Z, Yang S, Chen Y, et al.
Technol Cancer Res Treat . 2025 Mar; 24:15330338251328500. PMID: 40080898
Breast cancer is one of the leading causes of cancer-related deaths in women worldwide. Circular RNAs (circRNAs), a novel class of endogenous noncoding RNA with a covalently closed continuous loop...
2.
Pulavarthy V, Gundamaraju R
Technol Cancer Res Treat . 2025 Mar; 24:15330338251327465. PMID: 40080889
No abstract available.
3.
Fan F, Dong G, Han C, Luo Y, Li X, Dong X, et al.
Technol Cancer Res Treat . 2025 Mar; 24:15330338241309402. PMID: 40079761
Background and AimPredictors of neutrophil-to-lymphocyte ratio (NLR) and traditional clinical variables for hepatocellular carcinoma (HCC) prognosis after locoregional therapies were useful while exhibited modest prognostic performances. We dig out the...
4.
5.
Nagpal R, Campione M, Rebuzzi S, Fratino L, Rescigno P, Bracarda S, et al.
Technol Cancer Res Treat . 2025 Feb; 24:15330338251316626. PMID: 39989333
Background: The prognostic value of the Geriatric 8 (G8) screening score in metastatic renal cell carcinoma (mRCC) patients receiving first-line immunotherapy remains unclear. This study aimed to evaluate the prognostic...
6.
Zhou Z, Dong T, Wang B, Wang Z, Zhu H, Li W, et al.
Technol Cancer Res Treat . 2025 Feb; 24:15330338251322075. PMID: 39989262
Objective: To investigate the optimal radiotherapy regimen for synchronous bilateral breast cancer (SBBC) by utilizing dosimetric and radiobiological indicators, and to assess the impact of applying an optical surface monitoring...
7.
Rizwan M, Mahjabeen I, Haris M, Qayyum F, Kayani M
Technol Cancer Res Treat . 2025 Feb; 24:15330338251323314. PMID: 39989256
Exosomes play significant roles in transferring cargo materials like proteins, RNAs (including miRNAs), and DNA. However, the role of serum exosome shuttled RNAs and miRNAs in head and neck cancer...
8.
Karageorgos F, Karolos I, Pettas T, Tsioukas V, Pikridas C, Tsoulfas G
Technol Cancer Res Treat . 2025 Feb; 24:15330338251323138. PMID: 39980434
3-dimensional (3D) printing and augmented reality (AR) are emerging technologies that are used in a wide variety of scientific fields. Among them, medicine is one of the most promising fields...
9.
Zhang L, Zhang L, Shi Z, Mi Y, Zhang L, Shi X, et al.
Technol Cancer Res Treat . 2025 Feb; 24:15330338241305434. PMID: 39962891
Background: NUPR1 is a small molecule protein that plays an important role in tumor progression and drug resistance. Our previous study found that NUPR1 promotes the progression of bladder cancer,...
10.
Zhong L, Lu A, Lu X, Liu X, Cao L, Zhu S, et al.
Technol Cancer Res Treat . 2025 Feb; 24:15330338251319394. PMID: 39912261
Primary central nervous system lymphoma (PCNSL) is a very rare extranodal non-Hodgkin's lymphoma confined to the brain, eyes, spinal cord, and cerebrospinal fluid (CSF). This disease is highly aggressive. For...